CRVS

MKT CAP:$1B

Corvus Pharmaceuticals, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$17.85+$10.53 (+143.85%)

Apr 22, 2026

Company Details

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, ...

CEO

Richard A. Miller

IPO Date

Mar 23, 2016

Website

www.corvuspharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$15M

EPS (Diluted)

-$0.53

Free Cash Flow

-$33M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 12, 2026

$0EPS -$0.53

Q4 2025

Mar 12, 2026

$0EPS -$0.18

Q3 2025

Nov 4, 2025

$0EPS -$0.12

Q2 2025

Aug 7, 2025

$0EPS -$0.10

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$7M
Q2 22	$0	$0	-$7M
Q3 22	$0	$0	-$12M
Q4 22	$0	$0	-$6M
Q1 23	$0	$0	-$7M
Q2 23	$0	$0	-$6M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$6M
Q1 24	$0	$0	-$6M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$7M
Q4 24	$0	$0	-$8M
Q1 25	$0	$0	-$10M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	-$11M
Q4 25	$0	-$26.0K	-$12M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$6M	-$6M
Q2 22	-$6M	-$6M
Q3 22	-$7M	-$7M
Q4 22	-$8M	-$8M
Q1 23	-$8M	-$8M
Q2 23	-$5M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$5M	-$5M
Q1 24	-$5M	-$5M
Q2 24	-$5M	-$5M
Q3 24	-$6M	-$6M
Q4 24	-$8M	-$8M
Q1 25	-$8M	-$8M
Q2 25	-$6M	-$6M
Q3 25	-$10M	-$10M
Q4 25	-$9M	-$9M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$4.0K
Q3 22	$265.0K
Q4 22	$4.0K
Q1 23	$34.0K
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$36.0K
Q2 25	$113.0K
Q3 25	$0
Q4 25	$25.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-35.4%
Q2 22	—	-37.9%
Q3 22	—	+37.9%
Q4 22	—	-16.8%
Q1 23	—	-11.3%
Q2 23	—	-19.8%
Q3 23	—	-55.4%
Q4 23	—	-0.3%
Q1 24	—	-4.9%
Q2 24	—	+5.6%
Q3 24	—	+30.5%
Q4 24	—	+43.4%
Q1 25	—	+58.7%
Q2 25	—	+72.9%
Q3 25	—	+45.7%
Q4 25	—	+50.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$739.0K	—
Q2 22	$675.0K	—
Q3 22	$658.0K	—
Q4 22	$620.0K	—
Q1 23	$492.0K	—
Q2 23	$537.0K	—
Q3 23	$546.0K	—
Q4 23	$572.0K	—
Q1 24	$689.0K	—
Q2 24	$768.0K	—
Q3 24	$701.0K	—
Q4 24	$845.0K	—
Q1 25	$1M	—
Q2 25	$1M	—
Q3 25	$1M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$5M	$2M
Q2 22	$5M	$2M
Q3 22	$10M	$2M
Q4 22	$4M	$2M
Q1 23	$5M	$2M
Q2 23	$4M	$2M
Q3 23	$4M	$2M
Q4 23	$4M	$2M
Q1 24	$4M	$2M
Q2 24	$4M	$2M
Q3 24	$5M	$2M
Q4 24	$6M	$2M
Q1 25	$7M	$2M
Q2 25	$8M	$2M
Q3 25	$8M	$2M
Q4 25	$10M	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$31M	$31M	$63M
Q2 22	$28M	$28M	$57M
Q3 22	$25M	$25M	$50M
Q4 22	$13M	$29M	$42M
Q1 23	$10M	$25M	$34M
Q2 23	$8M	$29M	$37M
Q3 23	$20M	$12M	$32M
Q4 23	$13M	$15M	$27M
Q1 24	$7M	$15M	$22M
Q2 24	$15M	$32M	$47M
Q3 24	$5M	$37M	$42M
Q4 24	$9M	$43M	$52M
Q1 25	$5M	$39M	$44M
Q2 25	$15M	$60M	$74M
Q3 25	$3M	$63M	$66M
Q4 25	$5M	$52M	$57M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	47M	+0.0%	+34.9%
Q2 22	47M	0.0%	+10.2%
Q3 22	47M	0.0%	+5.9%
Q4 22	47M	0.0%	+0.0%
Q1 23	47M	+0.0%	+0.0%
Q2 23	47M	+2.0%	+2.0%
Q3 23	49M	+3.1%	+5.2%
Q4 23	49M	+0.1%	+5.3%
Q1 24	49M	0.0%	+5.3%
Q2 24	60M	+21.8%	+25.7%
Q3 24	67M	+11.7%	+36.2%
Q4 24	68M	+2.5%	+39.4%
Q1 25	75M	+10.0%	+53.3%
Q2 25	78M	+3.5%	+30.3%
Q3 25	83M	+6.5%	+24.2%
Q4 25	80M	-3.7%	+16.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	28
Q2 22	$0	28
Q3 22	$0	28
Q4 22	$0	29
Q1 23	$0	29
Q2 23	$0	29
Q3 23	$0	29
Q4 23	$0	28
Q1 24	$0	28
Q2 24	$0	28
Q3 24	$0	28
Q4 24	$0	31
Q1 25	$0	31
Q2 25	$0	31
Q3 25	$0	31
Q4 25	$0	200K

Revenue / Employee